Pages that link to "Q26823319"
Jump to navigation
Jump to search
The following pages link to Inventing new medicines: The FGF21 story (Q26823319):
Displaying 50 items.
- Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases (Q26744232) (← links)
- Implication of hepatokines in metabolic disorders and cardiovascular diseases (Q26751147) (← links)
- The Impact of Organokines on Insulin Resistance, Inflammation, and Atherosclerosis (Q26753189) (← links)
- Fibroblast Growth Factor Signaling in Metabolic Regulation (Q26772751) (← links)
- Neural Control of Energy Expenditure (Q26853654) (← links)
- Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders (Q27686803) (← links)
- Exercise and diabetes: relevance and causes for response variability (Q28081508) (← links)
- Serum FGF21 levels are associated with brown adipose tissue activity in humans. (Q30374773) (← links)
- Identification of novel inhibitors of the amino acid transporter B0 AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes. (Q32182366) (← links)
- Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues (Q33685319) (← links)
- FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases (Q33851027) (← links)
- A link between hepatic glucose production and peripheral energy metabolism via hepatokines (Q33906438) (← links)
- The good, the bad, and the unknown: Fructose and FGF21 (Q35040509) (← links)
- Mice lacking neutral amino acid transporter B(0)AT1 (Slc6a19) have elevated levels of FGF21 and GLP-1 and improved glycaemic control (Q35573369) (← links)
- Transcriptional control and hormonal response of thermogenic fat. (Q35589477) (← links)
- Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet (Q35613153) (← links)
- Biomarkers of insulin sensitivity and insulin resistance: Past, present and future (Q35652813) (← links)
- Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model (Q35813371) (← links)
- High-fat diet and FGF21 cooperatively promote aerobic thermogenesis in mtDNA mutator mice (Q35865700) (← links)
- Skeletal muscle mitochondrial uncoupling prevents diabetes but not obesity in NZO mice, a model for polygenic diabesity. (Q36300116) (← links)
- miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21. (Q36504308) (← links)
- Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis (Q36746670) (← links)
- The Nuclear Receptor Rev-erbα Regulates Adipose Tissue-specific FGF21 Signaling. (Q36898306) (← links)
- CREBH-FGF21 axis improves hepatic steatosis by suppressing adipose tissue lipolysis (Q37005595) (← links)
- Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity. (Q37034745) (← links)
- Metabolic Responses to Dietary Protein Restriction Require an Increase in FGF21 that Is Delayed by the Absence of GCN2 (Q37116027) (← links)
- FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice (Q37485018) (← links)
- Myostatin signals through miR-34a to regulate Fndc5 expression and browning of white adipocytes. (Q37570671) (← links)
- Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates (Q37571417) (← links)
- Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease (Q38325739) (← links)
- Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. (Q38633258) (← links)
- Vascular Endothelial Regulation of Obesity-Associated Insulin Resistance (Q38636437) (← links)
- Targeting nuclear receptors for the treatment of fatty liver disease (Q38678741) (← links)
- Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015). (Q38838461) (← links)
- Fgf21 regulates T-cell development in the neonatal and juvenile thymus (Q38880909) (← links)
- Hepatokines: unlocking the multi-organ network in metabolic diseases. (Q39000769) (← links)
- Fibroblast growth factor 21 night watch: advances and uncertainties in the field (Q39017842) (← links)
- Sleep Duration and Cardiometabolic Risk Among Chinese School-aged Children: Do Adipokines Play a Mediating Role? (Q40280560) (← links)
- Fibroblast activation protein (FAP) as a novel metabolic target (Q41166927) (← links)
- Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity via the SIRT1/LKB1/AMPK pathway (Q41167751) (← links)
- iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy (Q41440576) (← links)
- Genetic disruption of uncoupling protein 1 in mice renders brown adipose tissue a significant source of FGF21 secretion (Q41810632) (← links)
- Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. (Q42101410) (← links)
- A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response (Q42378996) (← links)
- Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action (Q42541271) (← links)
- FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia (Q47183309) (← links)
- Process development of a FGF21 protein-antibody conjugate. (Q47742925) (← links)
- Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. (Q49202758) (← links)
- Highly selective and sensitive measurement of active forms of FGF21 using novel immunocapture enrichment with LC-MS/MS. (Q49846751) (← links)
- GSK3 is a negative regulator of the thermogenic program in brown adipocytes. (Q50300813) (← links)